Investors
Investor News
- Data from the US NIH-led ACTIV-2 Phase 2 trial
- Interim Results
- Board Changes
- SPRINTER Long COVID data presented at IDWeek
- Notice of Interim Results
- Positive Findings from SG015 Trial Analysis
- Company Announce Collaboration on UNIVERSAL Trial
- Result of AGM
- Posting of Annual Report and Notice of AGM
- Full Year Results
- Synairgen presents at ATS 2022
- Presentation at ECCMID
- Synairgen to present at ATS 2022
- Synairgen provides update on ACTIV-2 Trial
- Update on SNG001
- Topline results from Phase 3 SPRINTER trial
- Synairgen announces partnership with Ashfield Engage